All In Biotech

BLA 125118 · Bristol Myers Squibb

Orencia

Abatacept · Iv (Infusion) · Selective T Cell Costimulation Modulator

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Dec 23, 2005

Approved uses

11

Original approval plus efficacy supplements

Registered trials

256

62 Phase 3, 34 recruiting

FAERS reports

139,985

83,534 serious, 9,486 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2025.

ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended. ( 1.5 , 5.1) 1.1 Adult Rheumatoid Arthritis ORENCIA ® is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). 1.2 Polyarticular Juvenile Idiopathic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). 1.3 Psoriatic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). 1.4 Prophylaxis for Acute Graft versus Host Disease ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor. 1.5...

Mechanism: Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. Activated T lymphocytes are implicated in the pathogenesis of RA, pJIA and PsA and are found in the synovium of patients with RA, pJIA and PsA. In vitro , abatacept decreases T-cell proliferation and inhibits the production of the cytokines TNF alpha (TNFα), interferon-γ, and interleukin-2. In a rat collagen-induced arthritis model,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORENCIA · ABATACEPT 250MG · INJECTABLE, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abatacept" as an intervention, any sponsor and status, largest first.

All 256 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective39,195
  • rheumatoid arthritis24,856
  • pain22,227
  • arthralgia21,734
  • joint swelling20,948
  • fatigue14,613
  • contraindicated product administered14,115
  • rash13,429
  • drug intolerance13,300
  • off label use12,277
  • arthropathy11,847
  • alopecia10,772

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200512
2006346
2007470
2008778
2009313
2010867
2011562
20121,591
20132,580
20142,967
20154,561
20166,760
20179,924
201812,798
201914,017
202018,058
202113,719
202213,229
20239,505
202410,625
20259,654
20266,634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orencia (Abatacept)

2024 spending

$184M

Beneficiaries

4,112

30,087 claims

Per beneficiary

$44,728

$1,406.77 per unit

View as table
YearSpending
2020$172,167,789
2021$168,467,143
2022$170,833,810
2023$178,400,675
2024$183,919,526

Part D: Orencia (Abatacept/Maltose)

2024 spending

$64.6M

Beneficiaries

2,034

13,822 claims

Per beneficiary

$31,743

$1,431.35 per unit

View as table
YearSpending
2020$29,667,287
2021$34,952,685
2022$45,960,310
2023$53,626,257
2024$64,565,143

Part B: Orencia* (Abatacept*) · HCPCS J0129

2024 spending

$930M

Beneficiaries

33,154

291,579 claims

Per beneficiary

$28,062

2024 ASP limit $43.29 per unit

View as table
YearSpending
2020$1,023,005,572
2021$988,943,742
2022$903,326,017
2023$902,527,110
2024$930,380,811

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 416 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.